Share
1,077 Posts.
lightbulb Created with Sketch. 92
clock Created with Sketch. 17/07/19
19:37
Share
Originally posted by RBx
↑
https://www.noxopharm.com/site/PDF/2021_4/NOXReleasesLatestNewsletter
Noxopharm is aware of only two non-nucleotide STING agonists under development, intended to deliver a STING effect on a general basis but limited to cancer cells. One is the compound, MAVU-104, a pre-clinical drug candidate under development by Seattle-based Mavupharma.16 Mavupharma was acquired this week by Abbvie. The second drug candidate is Veyonda®.
Abbvie, a biopharmaceutical company with ~30,000 employees and a market cap of $102 Billion, paid an undisclosed sum for a pre-clinical compound.
Veyonda is already in the clinic and appears to selectively activate STING in humans - i.e. in cancer cells alone. I am happy to hold until someone comes knocking on our door.
Expand
When the knock comes RBx, I'd suggest that all personnel at Noxopharm HQ are standing well clear. My suspicion could be true that it comes with the force of a Sherman tank.
